Heart failure & cardiomyopathiesMeta-analysis
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
- Systematic review and meta-analysis
- meta-regression
Authors' conclusion
SGLT2i significantly lower the risk of HF hospitalization and new HF diagnoses among cancer patients and survivors, with particularly pronounced benefits in breast cancer patients receiving anthracycline-based chemotherapy.
Study context
- Population
- Cancer patients and survivors
- Participants
- 88,273 patients · 13 studies
- Comparison
- SGLT2i vs no SGLT2i
- Outcome
- Heart failure (HF) hospitalization and new HF diagnoses
Pooled result
As reported in the abstract
SGLT2i vs No SGLT2iRelative risk (95% CI)P value
HF hospitalization; I² = 28%
0.49(0.36–0.66)
P < 0.01new HF diagnoses; I² = 71%
0.29(0.10–0.87)
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| HF hospitalization, breast cancer studies with ≥50% vs <50% of patients on anthracyclines (meta-regression) · multi-variate meta-regression | 0.0085 (0.0001–0.2645) | P = 0.0081 | |
| 0.050.21520Relative risk (log scale) |
Original publication
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol. Published 6 March 2025. doi:10.1093/eurjpc/zwaf026
Summarised from the published abstract; every number is checked against it